UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549

 
FORM 8-K

 
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event Reported):  June 14, 2016

 
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)

 
Cayman Islands
(State or Other Jurisdiction of
Incorporation)	 	001-36033
(Commission File Number)	 	98-1226628
(I.R.S. Employer Identification Number)	
 
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
Item 7.01 Regulation FD Disclosure.
 
The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
Theravance Biopharma, Inc. held a Key Opinion Leader (“KOL”) event in New York, NY on Tuesday, June 14, 2016 at which members of management presented updates regarding the Company’s GI-targeted pan-Janus kinase (JAK) inhibitor program, TD-1473.  The slide presentation is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
99.1	Theravance Biopharma’s Investor Slide Presentation: GI-Targeted JAK Inhibition for Ulcerative Colitis	
 
2

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	THERAVANCE BIOPHARMA, INC.	

Date: June 14, 2016	By:	/s/ Renee D. Gala	
 	 	Renee D. Gala	
 	 	Senior Vice President and Chief Financial
Officer	
 
3

 
EXHIBIT INDEX
 
Exhibit No.	 	Description	
99.1	 	Theravance Biopharma’s Investor Slide Presentation: GI-Targeted JAK Inhibition for Ulcerative Colitis	
 
4

Exhibit 99.1
GI-Targeted JAK Inhibition for Ulcerative Colitis Dr. Brett Haumann Chief Medical Officer

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements or projections. Examples of forward-looking statements in this presentation include statements relating to the company’s business plans and objectives, including financial and operating results, potential partnering transactions and sales targets, the company’s regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the company’s product and product candidates (including their potential as components of combination therapies and the timing and use of the net proceeds from the proposed offering). The company’s forward-looking statements are based on the estimates and assumptions of management as of the date of this presentation and are subject to risks and uncertainties that may cause the actual results to be materially different than those projected, such as risks related to delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities, and market conditions that may affect whether the offering will be made or consummated on the proposed terms, if at all. Other risks affecting the company are described under the heading “Risk Factors” and elsewhere in the company’s Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2016, and other periodic reports filed with the SEC. Cautionary Statement Regarding Forward-Looking Statements

Vision: Intestinal Targeting By Design Build on a long-standing foundation of developing drugs for the lung Topical delivery to the organ of interest Maximal therapeutic benefit targeted directly at the disease area Negligible systemic absorption to minimize systemic side effects

Vision: Intestinal Targeting By Design TPBH is transforming the conventional approach to oral JAK inhibition Adopts the same mindset as in respiratory disease Focuses on targeted maximal activity at the site of inflammation in the colonic wall Challenges the conventional approach to dosing oral JAK inhibitors

Vision: Intestinal Targeting By Design Previous oral JAK inhibitors were designed to be systemically active TIME BLOOD LEVEL Tofacitinib (illustrative) Organ Drug levels Small intestinal wall Low Portal vein High Systemic circulation High Large intestinal wall Low Stool Minimal

Organ Drug levels Small intestine +++ Portal vein +++ Systemic circulation +++ Large intestine + Stool - Vision: Intestinal Targeting By Design TD-1473 is designed to maximize local anti-inflammatory efficacy & minimize systemic exposure TIME BLOOD LEVEL Organ Drug levels Small intestinal wall Low Portal vein High Systemic circulation High Large intestinal wall Low Stool Minimal Organ Drug levels Small intestine +++ Portal vein +++ Systemic circulation +++ Large intestine + Stool - TIME BLOOD LEVEL Organ Drug levels Small intestinal wall Moderate Portal vein Moderate Systemic circulation Minimal Large intestinal wall Moderate Stool Moderate Tofacitinib (illustrative) TD-1473 (illustrative)

. Efficacy of Tofacitinib JAK Inhibition Driven by Local Exposure Preclinical PoC for maximizing therapeutic index with GI-restricted molecule Colon Plasma Tofacitinib Oral Delivery (PO) Tofacitinib Intracecal Delivery (IC) Disease activity Intracecal administration results in equivalent efficacy with 15-fold lower dose, similar colon concentration, and 80-fold lower plasma concentration Shen et al. Colon Targeted Delivery of Tofacitinib Inhibits Oxazolone-induced Colitis in Mice, Despite Low Systemic Exposure. European Crohn’s and Colitis Organisation Conference March 2016

TD-1473 Reduces Rodent Colitis without Systemic Immunosuppression Differentiated from tofacitinib in the same preclinical models TD-1473 produces an anti-inflammatory effect at 10X lower dose & 1000X lower plasma concentration than tofacitinib TD-1473 shows no evidence of dose-dependent immunosuppressive effect, in contrast to tofacitinib Anti-inflammatory Effect in Mouse Oxazolone Colitis Model Reduction in Splenic NK Cell Counts Plasma AUC 0.004 µg.hr/mL Plasma AUC 4.7 µg.hr/mL Oral TD-1473 Oral Tofacitinib Beattie et al. TD-1473, a Novel, Potent, and Orally Administered, GI-targeted, Pan-Janus Kinase (JAK) Inhibitor . European Crohn’s and Colitis Organisation Conference March 2016

In-vitro & Ex-vivo Biological Properties of TD-1473 Potent JAK Inhibitor in Biochemical, Cellular and Colon Tissue Assays T cell Epithelial IL-13 (JAK1/2) pSTAT6 IL-8 80 80 tofacitinib 50 25 GM-CSF (JAK2) pSTAT5 200 IL-4 (JAK1/2) pSTAT6 32 tofacitinib 126 40 tofacitinib 25 32 126 32 1260 IFNα (JAK1/TYK2) pSTAT1 32 IL-2 (JAK1/3) pSTAT5 IFNγ 32 63 IL-6 (JAK1/2) pSTAT3 158 IL-12 (JAK2/TYK2) pSTAT4 126 tofacitinib 0.8 0.6 0.3 13 JAK1 JAK2 JAK3 TYK2 0.1 0.1 1.6 0.3 JAK Kinase domain Ki or IC50 values in nM Monocyte Human IBD colon IL-4 (JAK1/2) pSTAT6 100 tofacitinib 50 Mouse isolated colon (intraluminal drug dosing) IFN-g (JAK1/TYK2) pSTAT1 3200 tofacitinib 4000 TD-1473 TD-1473 TD-1473 TD-1473 TD-1473 TD-1473

Disposition of TD-1473 in Rat Optimized for Intestinal Restriction and Low Systemic Exposure TD-1473 is present at high levels in the lumen and tissue throughout the rat digestive tract Systemic levels of TD-1473 are low due to limited absorption and high clearance Corresponding tissue:plasma ratio (<40:1) and content:plasma ratio (<400:1) for tofacitinib are low relative to TD-1473 Upper GI Lower GI 10 100 1000 10000 100000 1000000 TD-1473 Tofa Compartment to Plasma Ratio Content Tissue 10 100 1000 10000 100000 1000000 TD-1473 Tofa Compartment to Plasma Ratio Content Tissue

TD-1473 Phase I FIH Study Schema Study 0140: Nested SAD/MAD in Healthy Volunteers Primary Objective: To evaluate the safety and tolerability of TD-1473 in healthy subjects in single ascending doses (n=40) and 14-day multiple ascending doses (n=32) Secondary Objective: To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of TD-1473 in plasma, urine and stool of healthy subjects

TD-1473 shows a favorable tolerability profile A total of 476 patient-days of dosing TD-1473 was generally well tolerated as a single dose up to 1000mg and as multiple daily doses up to 300mg QD for 14 days No serious, moderate, or severe AEs were reported in subjects dosed with TD-1473 There were no adverse events leading to study drug discontinuation All treatment-emergent adverse events in subjects dosed with TD-1473 were mild in severity and short in duration Vital sign and ECG assessments did not demonstrate any clinically significant changes relative to placebo No clinically relevant changes in chemistry or hematology laboratory parameters relative to placebo

TD-1473 Single and Multiple Dose Plasma PK Dose-proportional exposures from 10 – 1000 mg TD-1473 appears rapidly in plasma with low systemic concentrations consistent with limited oral bioavailability At steady state, the plasma exposures of TD-1473 at daily doses of 30 mg and 100 mg were approximately 75-fold and 15-fold lower, respectively, as compared to the plasma exposure of tofacitinib at twice daily doses of 10 mg High levels of TD-1473 present in stool at low doses, consistent with stool concentrations seen in positive preclinical models Tofacitinib Comparison: Data Extracted from Dowty ME, et al. JPET 2014. Mean ± SD plotted Multiple Ascending Dose PK on Day 14 (normal scale) Time (hr) C o n c e n t r a t i o n ( n M ) 0 4 8 12 16 20 24 0 100 200 300 400 300 mg 100 mg 30 mg 10 mg TD-1473 (QD) Multiple Ascending Dose PK on Day 14 (log scale) PK profile is consistent with slow absorption throughout the length of the small and large intestine

TBPH plans to progress TD-1473 to a patient study Totality of evidence suggests a therapeutically relevant dose of TD-1473 can penetrate the colon wall with minimal release into the systemic circulation TBPH is encouraged by the evidence to date Compelling preclinical evidence in relevant disease models Demonstrates that systemic exposure is not a prerequisite Confirms that TD-1473 achieves high mural concentrations Low systemic exposures and no dose-related immunosuppression Favorable PK and tolerability profile in healthy human volunteers No serious adverse events following single or repeat dose administration No clinically relevant changes in ECG, vitals or labs relative to placebo Low systemic exposure even at multiples of the likely intended dose range TBPH will progress to a Phase 1b study in patients with moderately or severely active ulcerative colitis by end-2016